Takahiro Anzai

Dr. Takahiro Anzai

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
HYHirokazu Yagi
Hirokazu Yagi
MYMaho Yagi-Utsumi
Maho Yagi-Utsumi
RHRena Honda
Rena Honda
YOYusaku Ohta
Yusaku Ohta
TSTaiki Saito
Taiki Saito
Koichi KatoKoichi Kato
Koichi Kato
MCFD2 and ERGIC-53, which are the products of causative genes of combined factor V and factor VIII deficiency, form a cargo receptor complex responsible for intracellular transport of these coagulation factors in the early secretory pathway. In this study, using an NMR technique, we successfully identified an MCFD2-binding segment from factor VIII composed of a 10 amino acid sequence that enhances its secretion. This prompted us to examine possible effects of attaching this sequence to recombinant glycoproteins on their secretion. We found that the secretion level of recombinant erythropoietin was significantly increased simply by tagging it with the passport sequence. Our findings not only provide molecular basis for the intracellular trafficking of coagulation factors and their genetic deficiency but also offer a potentially useful tool for increasing the production yields of recombinant glycoproteins of biopharmaceutical interest.

8 December 2018 in Cancer Science
Verified
Journal Article
Open access
PDF file
MYMasahiro Yasunaga
Masahiro Yasunaga
SSShinji Saijou
Shinji Saijou
SHShingo Hanaoka
Shingo Hanaoka
TATakahiro Anzai
Takahiro Anzai
RTRyo Tsumura
Ryo Tsumura
YMYasuhiro Matsumura
Yasuhiro Matsumura
The present state of therapy for colorectal cancer (CRC) is far from satisfactory, highlighting the need for new targets for this disease. We identified a new CRC‐specific molecule, TMEM180, a predicted 11‐pass transmembrane protein that apparently functions as a cation symporter. We developed an anti‐TMEM180 mAb and then succeeded in humanizing the mAb. Immunohistochemistry (IHC) in CRC with the mAb showed a similar positivity rate as compared with anti‐epidermal growth factor receptor mAb, and IHC with anti‐TMEM180 mAb did not show staining in major organs used in this study. Immune electron microscopy clearly indicated that TMEM180 was present on the tumor exosome. The TMEM180 promoter region contains 10 hypoxia‐responsive element consensus sequences; accordingly, SW480 cells upregulated TMEM180 under low‐oxygen conditions. Anti‐TMEM180 mAb has in vitro antibody‐dependent cell‐mediated cytotoxicity and complement‐dependent cytotoxicity activity, and SW480 CRC xenografts were eradicated by the mAb. These data indicate that TMEM180 may be a new CRC marker and that a mAb against this protein could be used as antibody‐based therapy against CRC.

1 December 2019 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
TATakahiro Anzai
Takahiro Anzai
YMYasuhiro Matsumura
Yasuhiro Matsumura
New target molecules for diagnosis of and drug development for colorectal cancer (CRC) are always in great demand. Previously, we identified a new colorectal cancer-specific protein, TMEM180, and successfully developed an anti-TMEM180 monoclonal antibody (mAb) for the diagnosis and treatment of CRC. Although TMEM180 is classified as a member of the cation symporter family and multi-pass membrane protein, little is known about its function. In this study, we examined topology of this membrane protein and analyzed its function. Using a homology model of human TMEM180, we experimentally determined that the protein has 12 transmembrane domains, and that its N-terminal and C-termini are exposed extracellularly. Moreover, we found that the putative cation-binding site of TMEM180 is conserved among orthologs, and that its position is similar to that of melibiose transporter MelB. These results suggest that TMEM180 acts as a cation symporter. Our topological analysis based on the homology model provides insight into functional and structural roles of TMEM180 that may help to elucidate the pathology of CRC.

14 February 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
KTKenji Takashima
Kenji Takashima
Yoshikatsu KogaYoshikatsu Koga
Yoshikatsu Koga
TATakahiro Anzai
Takahiro Anzai
KMKayo Migita
Kayo Migita
TYToru Yamaguchi
Toru Yamaguchi
Tomonori YanoTomonori Yano
Tomonori Yano
Photoimmunotherapy (PIT) is a promising tumor-selective treatment method that uses light-absorbing dye-conjugated antibodies and light irradiation. It has been reported that IR700 fluorescence changes with light irradiation. The purpose of this study was to investigate the fluorescence intensity and antitumor effect of PIT using real-time fluorescence observation of tumors and predict the required irradiation dose. The near-infrared camera system LIGHTVISION was used to image IR700 during PIT treatment. IR700 showed a sharp decrease in fluorescence intensity in the early stage of treatment and almost reached a plateau at an irradiation dose of 40 J/cm. Cetuximab-PIT for A431 xenografts was performed at multiple doses from 0–100 J/cm. A significant antitumor effect was observed at 40 J/cm compared to no irradiation, and there was no significant difference between 40 J/cm and 100 J/cm. These results suggest that the rate of decay of the tumor fluorescence intensity correlates with the antitumor effect by real-time fluorescence imaging during PIT. In addition, when the fluorescence intensity of the tumor plateaued in real-time fluorescence imaging, it was assumed that the laser dose was necessary for treatment.

10 August 2015 in FEBS Letters
Verified
Journal Article
Closed access
PDF file
KIKoya Inagaki
Koya Inagaki
TSTadashi Satoh
Tadashi Satoh
MYMaho Yagi-Utsumi
Maho Yagi-Utsumi
AGAnne-Charlotte Le Gulluche
Anne-Charlotte Le Gulluche
TATakahiro Anzai
Takahiro Anzai
Koichi KatoKoichi Kato
Koichi Kato

6 July 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
TATakahiro Anzai
Takahiro Anzai
SSShinji Saijou
Shinji Saijou
HTHiroki Takashima
Hiroki Takashima
MHMisato Hara
Misato Hara
SHShingo Hanaoka
Shingo Hanaoka
MYMasahiro Yasunaga
Masahiro Yasunaga
Development of antibodies against the native structure of membrane proteins with multiple transmembrane domains is challenging because it is difficult to prepare antigens with native structures. Previously, we successfully developed a monoclonal antibody against multi-pass membrane protein TMEM180 by exosome immunization in rats. This approach yielded antibodies that recognized cancer-specific antigens on the exosome. In this study, we performed immunoprecipitation using magnetic beads to identify the antigen of one of the rat antibody clones, 0614, as CD73. We then converted antibody 0614 to human chimeric antibody 0614-5. Glioblastoma (GB) was the cancer type with the highest expression of CD73 in the tumor relative to healthy tissue. An antibody–drug conjugate (ADC) of 0614-5 exerted an antitumor effect on GB cell lines according to expression of CD73. The 0614-5-ADC has potential to be used to treat cancers with high CD73 expression. In addition, our strategy could be used to determine the antigen of any antibody produced by exosome immunization, which may allow the antibody to advance to new antibody therapies.